ArticleDiabetology & metabolic syndrome2025
Identification of the LncRNA PRNCR1/miR-642a-5p/SSTR3 CeRNA network and its diagnostic value in type 2 diabetes mellitus.
Article in Diabetology & metabolic syndrome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Immuno-Metabolic Reprogramming in Metabolic Syndrome and Its Cardiovascular Complications: An Integrative Bioinformatics Study.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveThis study aimed to investigate the expression and functions of long noncoding RNAs (lncRNAs) in circulating leukocytes related to type 2 diabetes mellitus (T2DM).
methodsWe conducted microarray analysis and RNA sequencing on peripheral blood mononuclear cells (PBMCs) from newly diagnosed T2DM patients and healthy controls. Differentially expressed lncRNAs, mRNAs, and miRNAs were identified using an absolute log
resultsA total of 531 DElncRNAs, 328 DEmRNAs, and 42 DEmiRNAs were identified in PBMCs from T2DM patients compared to healthy controls. The ceRNA network included 24 differentially expressed lncRNAs, 11 miRNAs, and 18 mRNAs. Functional enrichment analyses indicated that the differentially expressed mRNAs were mainly associated with pancreatic secretion, lipid metabolism, atherosclerosis, type I diabetes mellitus, and fluid shear stress. Furthermore, qRT-PCR validation confirmed the significant downregulation of prostate pancer associated non-coding RNA 1 (PRNCR1) and somatostatin receptor 3 (SSTR3), and the upregulation of miR-642a-5p. PRNCR1 and miR-642a-5p were positively correlated with triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), HbA1c, fasting plasma glucose (FPG), and homeostasis model assessment of insulin resistance (HOMA-IR), while negatively correlated with leptin and insulin. Conversely, SSTR3 was positively correlated with leptin and insulin, while negatively correlated with total cholesterol (TC), TG, LDL-C, HbA1c, FPG, and HOMA-IR. ROC curve analysis suggested that the expression of miR-642a-5p and SSTR3 could differentiate T2DM patients from healthy controls. Dual-luciferase and RIP assays confirmed that PRNCR1 could sponge miR-642a-5p, which in turn regulated SSTR3, and PRNCR1 knockdown was demonstrated to significantly downregulate SSTR3.
conclusionThese findings suggest that PRNCR1 may contribute to insulin secretion disorders in T2DM by regulating the miR-642a-5p/SSTR3 axis, and gained new insight into the potential mechanisms and pathways involved in T2DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.